The KLOW Blend: What’s In It and the Research on Each Component

What is the KLOW blend?

The KLOW blend — listed in the catalogue as “KLOW 80 mg” — is the name for a research preparation that supplies four peptides together: BPC-157, GHK-Cu, TB-500 and KPV. That is a naming and composition fact only: the label records which four sequences are in the preparation, not that they act together or that the combination has been studied as a unit.

A neutral way to place it in the catalogue: KLOW is the three GLOW peptides — BPC-157, GHK-Cu and TB-500 — plus KPV. That is a composition observation, not a claim that the additional peptide adds any benefit. Because the honest evidence for this preparation is the evidence for its four components, the rest of this page summarises each briefly and hands off to its full research page, then states plainly what the literature does and does not say about the four together.

The four components

BPC-157

A synthetic 15-amino-acid pentadecapeptide, a fragment of a gastric-juice protein first characterised in 1993. It is described as pleiotropic — no single receptor — with studies examining VEGFR2-associated angiogenesis, the nitric-oxide system and ERK1/2 signalling in models; the evidence is overwhelmingly preclinical. Full detail: BPC-157 research: mechanism & studies.

GHK-Cu

The copper(II) complex of the tripeptide Gly-His-Lys, first isolated from human plasma in 1973. Its literature is pleiotropic, with a distinctive gene-expression-profiling strand, studied largely in vitro, computationally and in animal models. Full detail: GHK-Cu research: copper peptide mechanism. No cosmetic outcome is stated here.

TB-500 (thymosin β4)

A synthetic peptide based on the actin-binding region of thymosin β4, a 43-amino-acid peptide. The best-characterised biochemistry is G-actin sequestration; the wider literature is pleiotropic and predominantly preclinical. Full detail: TB-500 research: thymosin β4 mechanism.

KPV

The C-terminal tripeptide of α-melanocyte-stimulating hormone (Lys-Pro-Val). The mechanisms examined — PepT1-mediated cellular uptake and reduced NF-κB / MAP-kinase inflammatory signalling — come from cell and rodent models, with essentially no human clinical trial data. Full detail: KPV research: mechanism & studies.

Is there research on the combination itself?

Stated plainly, because it is the point that matters most: the published literature studies BPC-157, GHK-Cu, TB-500 and KPV separately. There is essentially no dedicated, peer-reviewed research on all four administered as a single combination — no controlled study establishing what the four-peptide preparation does as a unit, and none comparing it against any component on its own.

Combining the four sequences into one research preparation is therefore a formulation and catalogue decision, not a finding. This page makes no claim that the four do anything together, and no claim that the blend outperforms any component or the three-peptide GLOW preparation. The four component pages above are the actual evidence base — and each of them is, on its own terms, largely preclinical.

It is worth being explicit about why the honest answer is “essentially none” rather than simply “not summarised here.” Peer-reviewed peptide research is built around single, defined molecules studied in isolation, so that any observed effect can be attributed to one compound; a four-peptide blend is instead assembled at the catalogue and formulation stage. A study of BPC-157, GHK-Cu, TB-500 and KPV given together would be a separate piece of work with its own design and controls, and no such study exists in a form this page could responsibly cite. The relationship to GLOW is likewise a composition observation only — adding KPV to the three-peptide set changes what is in the vial, not what the published record establishes, which remains the four separate, and largely preclinical, literatures described above.

Blend vs separate vials — a formulation fact

The catalogue lists KLOW 80 mg in two forms: as a co-formulated blend, and as separate vials of the four peptides. That is a packaging and formulation description — one vial versus four — and an identity fact, not a protocol or a ratio presented as a regimen. The milligram figure on the label is a catalogue quantity that identifies the material, not a dose, and this page gives no per-use amount, timing, or administration detail.

Research-grade sourcing and verification

For laboratory research use only, the KLOW preparation is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. For a four-peptide preparation that includes a copper complex, per-sequence identity — and, for the copper tripeptide, copper content and stoichiometry — are part of a reproducible material. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Chang C-H, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon fibroblasts.” 2011 (PMC6271067). (BPC-157 component.)
2. Vasireddi N, et al. “Systematic review of BPC-157 in orthopaedic sports medicine.” 2025. (BPC-157 component.)
3. Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International. 2015 (PMC4508379). (GHK-Cu component.)
4. Carlier MF, Jean C, Rieger KJ, Lenfant M, Pantaloni D. “Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio.” PNAS. 1993;90(11):5034–5038. (TB-500 component.)
5. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.” Gastroenterology. 2008;134(1):166–178. PMID 18061177. (KPV component.)
6. Getting SJ, Schiöth HB, Perretti M. “Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.” J. Pharmacol. Exp. Ther. 2003;306(2):631–637. PMID 12750433. (KPV component.)